CSL (ASX:CSL) share price wobbles on COVID vaccine news

The CSL Limited (ASX: CSL) share price is on watch after the UK found "possible links" between the AstraZeneca vaccine and blood clots.

| More on:
A man looking sheepish grits his teeth and looks to the side

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is a little wobbly this morning after negative vaccine news overnight from the United Kingdom.

The pharmaceutical giant, which produces and supplies the AstraZeneca PLC (LSE: AZ) COVID-19 vaccine in Australia, is trading close to its opening price after news that the UK medical regulator has found a "possible link" between the vaccine and blood clotting in younger adults. The regulator noted that blood clotting was considered a rare side-effect of the vaccine.

At the time of writing, the CSL share price is trading flat around $263 as Australian investors digest the news out of the UK.

What's driving the CSL share price?

The Medicines and Healthcare products Regulatory Agency (MHRA) released a statement overnight concluding the evidence of a causal link between blood clotting and receiving the AstraZeneca vaccine in low platelet individuals was stronger than previously thought, but not conclusive.

The agency said the risk of blood clotting decreased with age and was "extremely rare and unlikely to occur". 

Its statistics suggested the risk of developing a blood clot after the first vaccine dose was 1 in 250,000 (0.0004%) and the risk of a fatal blood clot was 1 in 1 million (0.0001%). Despite this, the UK will provide alternative vaccines to the under 30s if possible.

The World Health Organisation (WHO) responded to the UK news, saying evidence of the link, while plausible, was not yet confirmed. It also noted the risk of catching and dying from COVID-19 was much higher than the risk of the vaccine.

What did our top doctor say?

Australia's chief medical officer, Professor Paul Kelly told ABC Radio:

There seems to be a trend in younger people and, at least in the European data in women being more common, but I would really stress these are extremely rare events and like with any treatment… we have to look at the risk and benefit.

And we do know that the benefits of vaccinations against this very serious diseases Covid is a really important component of our control…

Ultimately it will be a decision by the Australian Government about what that means for the vaccine rollout.

Australia's position

Australia is primarily relying on the AstraZeneca vaccine in the fight against COVID. The government has contracted CSL to develop the vaccine locally.

Both the imported and locally manufactured AstraZeneca vaccine have already been approved by the Therapeutics Good Administration (TGA).

Speaking about the developments this morning, Prime Minister Scott Morrison said Australia's medical experts would look at the data before making new recommendations to the government.

The Prime Minister also stressed the extremely low chances of people experiencing blood clotting from the vaccine. He advised that at present, the vaccine rollout would not be affected by the latest developments.

Motley Fool Australia reached out to CSL for comment, but none was received before publication.

Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

young woman reviewing financial reports at desk with multiple computer screens
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these stocks.

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Share Fallers

Why Bell Financial, IPD, Megaport, and Resolute Mining shares are falling today

These shares are starting the week in the red. But why?

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Share Gainers

Why Liberty, Lovisa, Novonix, and SG Fleet shares are storming higher today

These shares are starting the week strongly. But why? Let's find out.

Read more »

Shot of a young businesswoman looking stressed out while working in an office.
Industrials Shares

This ASX share is tumbling 13% on reduced earnings forecast

Earnings are expected to fall in the first half, much to the dismay of the market.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Mergers & Acquisitions

Guess which ASX All Ords stock just rocketed 23% on a $1.2 billion offer

Investors are piling into the ASX All Ords stock amid a $1.2 billion takeover bid.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Technology Shares

Why today is a big day for Pro Medicus shares

Records are being broken by this share on Monday. What's going on?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Opinions

3 reasons the GQG share price looks like a buy to me

Here’s why the fund manager could be good value.

Read more »

Young man looking afraid representing ASX shares investor scared of market crash
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »